| Production and delivery challenges set up turbulent Year of the Vaccine | 
  			  			  			  			  				| As 2020 closes, regulatory approval of COVID-19 vaccines has raised hopes the world can defeat the pandemic next year. But production and delivery challenges suggest beating the disease will be a marathon whose finish line is still far away.  
 Europe on Monday followed Britain and the United States in giving a green light to a COVID-19 vaccine from Pfizer (NYSE:PFE) and its partner BioNTech which, like a similar shot from Moderna (NASDAQ:MRNA) that has U.S. emergency approval, demonstrated 95% efficacy in large trials.
 | 
  			  			  				|  | 
  			  			  			  			  				|  | 
  			  			  			  			  			  			      			  			  			  			  				|  | 
  			  			  				  					| Most Popular Analysis | 
  				  				  				  					|  | 
  				  				  				  					|  | 
  				  				  				  					|  | 
  				  				  				  					|  | 
  				  				  				  					|  | 
  				  				  				  					| Show More Analysis » | 
  				    				  				  					| Weekly Comic | 
  				  					| Wall Street's Blockbuster Year Comes To A Close. Merry Christmas and Happy Holidays From Investing.com! | 
  				  					|   | 
  				  					| Show More Comics » | 
  				  			  			  			  			      			  			  				|  | 
  			    		
  		  		  		    
沒有留言:
張貼留言